Drug Trial Radar · NCT05650554
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older
Last checked: Nov 20, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
682
Actual
Start
Dec 12, 2022
Primary completion
Apr 2, 2024
Study completion Apr 2, 2024
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 3 dose levels of Quadrivalent Influenza messenger ribonucleic acid (mRNA) Vaccine MRT5413 compared to an active control (QIVstandard-dose (SD), QIV high-dose (HD) \[adults ≥ 65 years of age only\], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.
Conditions
- Influenza Immunization
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5413Biological
Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
Quadrivalent Recombinant Influenza VaccineBiological
Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
Quadrivalent Influenza Standard Dose VaccineBiological
Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe Route of Administration: Intramuscular injection
Quadrivalent Influenza High-Dose VaccineBiological
Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe Route of Administration: Intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with immediate adverse events (AEs)Time frame: Within 30 minutes after injection
- Number of participants with solicited injection site or systemic reactionsTime frame: Up to 7 days after injection
- Number of participants with unsolicited AEsTime frame: Up to 28 days after injection
- Number of participants with medically attended adverse events (MAAE)sTime frame: Up to 180 days after injection
- Number of participants with serious adverse events (SAEs)Time frame: From Day one to Day 366
- Number of participants with out-of-range biological test resultsTime frame: Up to 8 days after injection
- Individual Hemagglutination inhibition (HAI) titerTime frame: At Day 1 and Day 29
- Percentage of participants with detectable antibody HAI titers greater than or equal to (≥) 10 [1/dil]Time frame: At Day 1 and Day 29
- Individual HAI titer ratioTime frame: At Day 1 and Day 29
- Number of participants archiving HAI seroconversion against AntigensTime frame: At Day 1 and Day 29
- Percentage of participants with antibody HAI titers greater than or equal to (≥) 40 [1/dil]Time frame: At Day 29
- Percentage of participants with 2-fold and 4-fold rise in HAI titersTime frame: At Day 1 and Day 29
Locations
35 sites in 3 countries. Site status is shown where the registry gives one.
Velocity Clinical Research-Chula Vista Site Number : 8400061
Chula Vista, California
Velocity Gardena Site Number : 8400062
Gardena, California
Long Beach Clinical Trials Site Number : 8400052
Long Beach, California
Velocity Clinical Research, North Hollywood Site Number : 8400051
North Hollywood, California
California Research Foundation Site Number : 8400006
San Diego, California
Accel Clinical Research-Deland Clinical Research Unit Site Number : 8400032
DeLand, Florida
Velocity New Smyrna Beach Site Number : 8400063
Edgewater, Florida
SIMEDHealth, LLC Site Number : 8400014
Gainesville, Florida
Indago Research and Health Center Site Number : 8400044
Hialeah, Florida
Cenexel Research Centers of America Site Number : 8400011
Hollywood, Florida
Florida International Research Center Site Number : 8400045
Miami, Florida
Suncoast Research Associates, LLC Site Number : 8400060
Miami, Florida
Florida Pulmonary Research Center Site Number : 8400036
Winter Park, Florida
Meridian Clinical Research Site Number : 8400022
Savannah, Georgia
Velocity Clinical Research Site Number : 8400024
Meridian, Idaho
DM Clinical Research - Chicago Site Number : 8400025
River Forest, Illinois
Brengle Family Medicine Site Number : 8400039
Indianapolis, Indiana
Velocity Clinical Research Lincoln Site Number : 8400049
Lincoln, Nebraska
Meridian Clinical Research Site Number : 8400017
Norfolk, Nebraska
Velocity Clinical Research Site Number : 8400008
Omaha, Nebraska
Rochester Clinical Research. Inc. Site Number : 8400027
Rochester, New York
Velocity Clinical Research Site Number : 8400001
Cleveland, Ohio
Velocity Clinical Research - Providence Site Number : 8400019
East Greenwich, Rhode Island
Coastal Carolina Research Center Site Number : 8400042
North Charleston, South Carolina
ClinSearch Site Number : 8400013
Chattanooga, Tennessee
Elligo Health Research, Inc. Site Number : 8400002
Austin, Texas
DM Clinical Research- Bellaire Site Number : 8400026
Houston, Texas
Clinical Trials of Texas, Inc. - PPDS Site Number : 8400016
San Antonio, Texas
Investigational Site Number : 0360004
Darlinghurst, New South Wales, Australia
Investigational Site Number : 0360005
Kanwal, New South Wales, Australia
Investigational Site Number : 0360003
Maroubra, New South Wales, Australia
Investigational Site Number : 0360001
Morayfield, Queensland, Australia
Investigational Site Number : 0360002
North Melbourne, Victoria, Australia
Investigational Site Number : 6300001
Barrio Sabana, Puerto Rico
Investigational Site Number : 6300002
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.